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1.0 Background  
There is an ongoing debate about the harms and benefits of implementing a national screening 
programme for prostate cancer. The screening test (Prostate Specific Antigen, PSA) has poor 
sensitivity and specificity, meaning it produces a high proportion of false positive and false 
negative results. The PSA screen is followed by a biopsy which itself has relatively poor 
sensitivity. The screen test and biopsy are unable to distinguish between aggressive and 
indolent cancer, which may never cause symptoms within a man’s lifetime. The subsequent 
radical treatments for screen and biopsy detected prostate cancer may impact significantly on 
quality of life and resources. The potential benefits of screening are for those men who have 
aggressive prostate cancer that is destined to progress, because the cancer is identified and 
treated earlier than in clinical practice, potentially improving life expectancy. Other screen 
detected men are, on the other hand, subjected to unnecessary tests and radical treatments.  
Since the mid-1990s, there have been many model-based economic evaluations published 
assessing the cost-effectiveness of screening for prostate cancer, using a variety of modelling 
methods that in turn may impact the results from the model. As new data become available and 
new models are generated to incorporate these, it is important to learn from previous models. 
Therefore, a systematic review is required to identify the range of modelling methods that have 
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been employed to carry out an economic evaluation of screening for prostate cancer, the 
challenges that have been faced and the solutions that have been developed. 
 
1.1 Aim 
The aim of this study was to undertake a systematic review of these model-based cost-
effectiveness analyses of to summarise the current evidence base and identify which modelling 
methods are most appropriate for assessing the cost-effectiveness of different screening 
strategies for prostate cancer. 
 
To achieve this aim, a systematic review will be carried out with the following objectives: 
1. Identify the policy question and context of the model-based evaluations 
2. Collate evidence on the variability in model types, structures and assumptions used as 
well as the justification provided  
3. Identify the evidence base for the decision model  
4. Determine how uncertainty has been quantified in the decision models 
5. Synthesise the data to draw out key issues  
 
2.0 Methods 
An initial scoping search was carried out in March 2016 to determine whether any systematic 
reviews have previously been conducted and to identify the most appropriate search terms. 
Four relevant reviews were identified; on review was carried out as part of a report for Cancer 
Research UK (personal comms Wolstenholme) and the other was part of a report to the UK 
National Screening Committee [1]. The remaining two reviews were published in peer 
reviewed journals [2,3]. However, the two published reviews did not specifically review the 
details related to the modelling methods and the findings do not answer the specific review 
question here. As new model-based economic evaluations in the area have been published since 
the two reports (2010; 2011) and there is a lack of consistency in the studies identified in all of 
the reviews, it is necessary to conduct an up-to-date systematic review. 
The guidelines by the Centre for Reviews and Dissemination, Cochrane collaboration for 
reviews and PRISMA for reporting will be followed [4-6]. The review is restricted to evidence 
5th April 2016 
  3 
 
from the last 10 years (January 2006) to reflect current practice both in screening for prostate 
cancer and economic evaluation modelling methods. 
 
2.1 Search strategy 
 
Search terms 
The search terms will include prostate cancer and screening or testing and economic 
evaluation or cost-effectiveness and their variants (See appendix 1 for details) 
The search strategy consists of MeSH terms and free text terms. Search terms for economic 
evaluation and prostate cancer screening are based on previously published reviews [1,7], key 
words used in the known model-based economic evaluations of prostate cancer and those used 
by CRD to retrieve economic evaluations.  
 
Databases 
In April 2016, four electronic databases, the NICE website, UK National Screening Committee 
and reference lists from relevant studies will be searched for literature published between 
January 2006 and April 2016. If required, an update search will be carried out. 
Search strategies will be developed for the NHS Economic Evaluation Database (EED) (2006-
2014), Medline (2006-2016), EMBASE (2006-2014) and HTA databases (2006-2014).  
The NHS EED search was only ran up to 2014 because the database no longer runs searches 
of other databases to identify economic evaluations, the last search was at the end of 2014.  
Reports from NICE and UK National Screening Committee reports are also considered as these 
studies are important inputs to UK decision-making and can inform practice in other countries. 
 
Study selection and inclusion criteria 
Studies will be included if they meet the following criteria:  
 Model-based economic evaluation of PSA screening strategies for prostate cancer  
 Comparator of no screen or any screening interval  
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 Cost-effectiveness, cost-utility analysis, cost-consequence analysis, cost-benefit 
analysis  
 Model-based economic evaluation using primary or secondary data  
 Any PSA threshold for determining a positive result 
 Any subsequent treatments following the PSA screen 
 Any country and context 
 An outcome of QALYs or life years gained/saved 
 Natural history models of prostate cancer that did not include an economic evaluation, 
but were used to inform the model structure   
 
The study selection will be carried out in two stages:  
Firstly, the titles and abstracts of the identified studies will be assessed against the inclusion 
criteria to identify potentially relevant papers. 10% of the titles and abstracts will be reviewed 
by a second reviewer (SM). Where it is unclear if a study should be included it will be carried 
forward to the next stage and if an abstract is not provided the full text of the paper will be 
retrieved. 
Secondly, the full text of the papers that may be relevant will be screened. Those studies that 
are deemed to be relevant following review of the full text will then be carried forward to the 
data extraction process. All of the full text papers will be reviewed by a second reviewer (SM). 
Disagreements about study eligibility will be discussed and if they are not resolved a third 
reviewer will be consulted and a decision made by consensus.  
 
Data extraction 
Data extraction forms will be developed and pilot-tested on a random sample (5%) of included 
studies, and refined accordingly. Data extraction will be performed independently by two 
reviewers (SS, SM). Disagreement will be resolved by discussion between the two review 
authors. 
Information will be extracted from each included study on: 
1) The policy question and context (including the comparators and country) 
5th April 2016 
  5 
 
2) Characteristics of the screening strategy (including frequency of screening, starting age 
and PSA threshold for a positive result) 
3) Type of treatments and biopsies  
4) Type of outcome measure (including cost per QALY gained and life-year gained) 
5) Cost-effectiveness result  
6) Characteristics of the model (including model type, structure, handling of disease 
natural history) 
7) Sensitivity analysis (including the extent to which uncertainty in the cost-effectiveness 
result had been quantified.  
8) Evidence base for quality of life, resource use and adverse effects 
9) Reporting of overdiagnosis and overtreatment 
10) Other key areas included quantification of overdiagnosis and overtreatment, the 
clinical basis for the model (stage or grade progression), and the method for 
incorporating quality of life and resource use. 
 
Quality assessment 
As the purpose of the review was to report the methodological approaches used in model-based 
economic evaluations, a formal quality checklist was not used to select studies, but relevant 
sections of an existing economic evaluation checklist along with recommendations from NICE 
were used to evaluate studies [8,9]. In addition, key clinical issues that are known to be a 
concern in prostate cancer were included, such as reporting and capturing of overdiagnosis. 
The methodological components that will be assessed include appropriateness of: (1) screening 
strategies and treatments considered, (2) reporting of overdiagnosis and overtreatment (3) 
appropriateness of model inputs, (4) consistency of model structure with disease pathway 
theory, (5) model type and justification, (6) time horizon of analysis, (7) cycle length and 
justification, (8) model inputs and data modelling (including baseline data, cost and quality of 
life), and (9) assessment of uncertainty.  
 
Data synthesis 
A narrative synthesis of data will be taken and therefore a discussion reflecting on the 
modelling methods used and the impact on the cost-effectiveness will be provided. As the 
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purpose of the review is to identify key issues in modelling screening for prostate cancer and 
the types of modelling methods used, the quality of the studies is not assessed in relation to 
deciding whether they are included in the review. Rather, analysis of quality issues will form 
part of the synthesis.  
 
3.0 Dissemination 
The review findings will be disseminated at conferences, including the 2016 symposium on 
‘Methods for Evaluating Biomarkers and Tests’ and published in a peer reviewed journal such 
as Medical Decision Making, Value in Health or a high profile prostate cancer journal.  
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Appendix 
Appendix 1: Search terms 
Search terms on prostate cancer were adapted from the 2015 HTA report by Ramsay et al [7] 
on Ablative therapy for people with localised prostate cancer: a systematic review and 
economic evaluation. Screening terms were adapted from the Chilcott et al [1] report. 
Economic search terms were based on the search terms used by analysts to retrieve evidence 
for the NHS EED. 
 
Ovid - Medline  
1. exp prostatic neoplasms/  
2. (cancer adj3 (prostate or prostatic)).tw.  
3. (carcinoma adj3 (prostate or prostatic)).tw.  
4. (neoplas$ adj3 (prostate or prostatic)).tw.  
5. (malignan$ adj3 (prostate or prostatic)).tw 
6. (prostat$ adj3 (neoplasm$ or cancer or carcinoma or tumo?r$ or malignan$)).tw 
7. 1 or 2 or 3 or 4 or 5 or 6  
8. Prostate-Specific Antigen/ 
9 (prostate specific antigen or prostate-specific antigen or psa) tw 
10. Mass screening/ 
11. (Screen$ or test$) tw 
12. 8 or 9 or 10 or 11 
13. exp “costs and cost analysis”/ 
14. (model adj3 (economic or cost)).tw. 
15. (cost adj3 (effect$ or util$)).tw. 
16. (economic adj3 (anal$ or eval$)).tw. 
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17. (natural history model) tw 
18. (screen$ model$) tw 
19. (disease progression model$) tw 
20. 13 or14 or 15 or 16 or 17 or 18 or 19 
21. 7 and 12 and 20 
22. limit 12 to yr=”2006-Current” 
 
Ovid - EMBASE 
1. prostatic neoplasms [not a MESH term]  
2. exp prostate tumor/ [broader than cancer] 
3. (cancer adj3 (prostate or prostatic)).tw.  
4. (carcinoma adj3 (prostate or prostatic)).tw.  
5. (neoplas$ adj3 (prostate or prostatic)).tw.  
6. (malignan$ adj3 (prostate or prostatic)).tw 
7. (prostat$ adj3 (neoplasm$ or cancer or carcinoma or tumo?r$ or malignan$)).tw 
8. 1 or 2 or 3 or 4 or  5 or 6 or 7 
9. Prostate-Specific Antigen/ 
10 (prostate specific antigen or prostate-specific antigen or psa) tw 
11. Mass screening/ 
12. (Screen* or test*) tw 
13. 9 or 10 or 11 or 12 
14. exp Economic evaluation/ 
15. (model adj3 (economic or cost) 
16. (cost adj3 (effect$ or util$)) 
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17. (economic adj3 (anal$ or eval$) 
18. (natural history model) tw 
19. (screen$ model$) tw 
20. (disease progression model$) tw 
21. 14 or 15 or 16 or 17 or 18 or 19 or 20 
22. 8 and 13 and 21 
23. limit 12 to yr=”2006-Current” 
 
Cochrane – NHS EED  
#1 MeSH descriptor: [Prostatic Neoplasms]  
#2 (prostat* NEAR/3 (neoplasm* or cancer or carcinoma or tumor* or tumour* or 
malignan*)):  
#3 screen* or test*  
#4 MeSH descriptor: [Mass screening]   
#5 (prostate specific antigen or prostate-specific antigen or psa) tw 
#6 Prostate-Specific Antigen/ 
#7 #1 or #2 
#8 #3 or #4 or #5 or #6 
#9 #7 and #8 
#10 limit publication year from 2006 to 2016, in Economic Evaluations 
 
Cochrane - HTA 
#1 MeSH descriptor: [Prostatic Neoplasms]  
#2 (prostat* NEAR/3 (neoplasm* or cancer or carcinoma or tumor* or tumour* or 
malignan*)):  
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#3 screen* or test*  
#4 MeSH descriptor: [Mass screening]   
#5 (prostate specific antigen or prostate-specific antigen or psa) tw 
#6 Prostate-Specific Antigen/ 
#7 #1 or #2 
#8 #3 or #4 or #5 or #6 
#9 #7 and #8 
#10 limit publication year from 2006 to 2016, in Technology Assessments 
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Appendix 2: Data extraction forms 
Data extraction form for systematic review of model-based economic evaluation methods in 
prostate cancer screening. 
Reviewer  Date 
Author Year of study 
Title  Publication type 
Study objective  
  
Study characteristics  
Screening strategy Comparator 
Setting Geographical location 
Population  -Participant age/ethnicity Treatments considered 
PSA threshold Biopsy type 
Economic evaluation type Outcome measure 
  
Economic evaluation   
Perspective Direct costs & source 
Measure of benefit used/valuation method/ 
population elicited & year 
Indirect costs & source 
Evidence source for quality of life  Currency 
  
Decision model  
Model type & justification Time horizon & justification 
Model structure & justification Time cycle & justification 
Model pathway & justification Software used 
  
Natural history model/ comparator  
Characterisation of disease(stage and grade) Evidence source for pathway 
Data sources   
  
Sensitivity analysis Cost-effectiveness result 
Subgroup analysis  
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Methods for uncertainty analysis 
(probabilistic sensitivity analysis/ 
Deterministic sensitivity analysis) 
 
  
Other  
Method for incorporating sensitivity and 
specificity 
 
Methods for handling conditional 
dependence between screen and biopsy  
 
How is overdiagnosis assessed and 
reported? 
 
How is overtreatment assessed and 
reported? 
 
  
 
 
